VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
CSL Limited vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
CSL Limited
CSL · ASX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: CSL Limited leads (77 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: CSL Limited has 3 segments (71.7% in CSL Behring); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: CSL Limited has 7 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
CSL Limited
CSL Behring
Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases
Global
Hospitals, specialty pharmacies, physicians; payers and national health systems
Vertically integrated biopharma (plasma collection -> fractionation/manufacturing -> commercial distribution)
71.7%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
CSL Limited strengths
Gilead Sciences, Inc. strengths
Segment mix
CSL Limited segments
Full profile >CSL Behring
Oligopoly
CSL Seqirus
Oligopoly
CSL Vifor
Oligopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.